Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7617376 | 0.82 | HTT (0.30) | — | |
| SCHEMBL18894149 | 0.77 | GRIN2D (0.32) | — | |
| SCHEMBL7623286 | 0.69 | HTT (0.38) | ALDH1A1 | |
| SCHEMBL18894153 | 0.69 | ADRB2 (0.32) | — | |
| SCHEMBL8561076 | 0.68 | — | — | |
| SCHEMBL11038432 | 0.65 | HSD17B10 (0.52) | MAPTTTRALDH1A1CYP3A4TSHR | |
| SCHEMBL18894184 | 0.63 | — | — | |
| SCHEMBL6665560 | 0.62 | CBFB (0.42) | ALDH1A1 | |
| SCHEMBL16293605 | 0.62 | GRIN2D (0.41) | — | |
| SCHEMBL25828290 | 0.61 | HSD17B10 (0.48) | MAPTTTRALDH1A1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136310-B2 | Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors | UCB Biopharma SRL (BE) | 2021-10-05 | — | — | US | disclosed |
| US-20200283416-A1 | IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS | CELLTECH R&D LIMITED (GB) | 2020-09-10 | — | — | US | disclosed |
| EP-3380464-A1 | IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS | UCB Biopharma SPRL (BE) | 2018-10-03 | — | — | EP | disclosed |
| WO-2017089453-A1 | IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283416-A1 | IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS | PEPD, ADAM17, ANPEP | MAPT 961/4885AMY1A 4015/4885TTR 3145/4885 |
| US-11136310-B2 | Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors | PEPD, ADAM17, ANPEP | MAPT 961/4885AMY1A 4015/4885TTR 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.